Matinas BioPharma MTNB 深 沪
等待开盘 09-17 09:30:00 美东时间
0.1651
+0.005
+3.19%
华盛通- 最 高0.1698
- 今 开0.1612
- 成交量 72.61万股
- 最 低 0.1552
- 昨 收 0.16
- 总市值 242.58万
- 52周最高 1.99
- 市盈率 静 --
- 换手率 4.94%
- 52周最低 0.1505
- 委 比 -33.33%
- 总股本 1469.28万
- 历史最高 197.50
- 量 比 0.56
- 振 幅 9.13%
- 历史最低 0.1505
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Matinas BioPharma gets 2027 window to restore NYSE American listing compliance
Matinas BioPharma Holdings (MTNB) announced on Friday that it received a non-compliant notice from NYSE American for falling below its stockholders’ equity requirement. The company had $1.8M in stockh...
09-05 05:16
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Matinas BioPharma Holdings, Inc. received a notice from NYSE American regarding noncompliance with continued listing standards due to insufficient stockholders’ equity and consecutive losses. The company has submitted a compliance plan with a deadline of October 2, 2027. Its shares remain listed on NYSE American but are marked as noncompliant. The company focuses on developing therapies using lipid nanocrystal technology, including MAT2203, a pot...
09-04 21:00
BTIG Terminates Sales Agreement With Matinas BioPharma, Effective Immediately On July 23; Incurs No Termination Penalties Or Expenses From Sales Agreement Termination
As previously disclosed, on July 2, 2020, Matinas BioPharma Holdings, Inc. (the "Company") entered into an At-The-Market Sales Agreement (the "Sales Agreement") with BTIG, LLC ("BTIG"), pursuant to which the Company could offer and sell shares of its common stock, par value $0.0001 per share ("Commo...
07-25 05:11
Matinas Biopharma Holdings shares are trading lower. The company announced it entered into a definitive purchase agreement to sell Matinas BioPharma Nanotechnologies, Inc., including MAT220 to Azurity Pharmaceuticals.
Matinas Biopharma Holdings shares are trading lower. The company announced it entered into a definitive purchase agreement to sell Matinas BioPharma Nanotechnologies, Inc., including MAT220 to Azurity Pharmaceuticals.
07-13 20:48
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
Matinas BioPharma Holdings, Inc. has entered into a definitive business combination agreement with GH Power Inc. to create a publicly traded clean energy company focused on modular carbon-free energy, green hydrogen, and critical materials. The transaction is expected to provide a public market platform to accelerate commercialization and growth across North America and Europe. Additionally, Matinas has agreed to sell its subsidiary, Matinas BioP...
07-13 12:00
Matinas BioPharma Granted NYSE American Compliance Extension
The latest announcement is out from Matinas BioPharma ( ($MTNB) ). On June 24, ...
06-27 05:52
Matinas BioPharma faces NYSE notice over equity shortfall; gets until 2027 to comply
Matinas BioPharma (MTNB) announced on Friday that it received a notice from NYSE American for not meeting the exchange's minimum shareholder equity requirement. The company's shareholder equity fell t...
06-27 05:38
